Pimavanserin

BreastfeedingGeriatricPediatric
  • TRADE NAME: Nuplazid (Acadia)
  • INDICATIONS: Hallucinations and delusions associated with Parkinson’s disease psychosis
  • CLASS: Antipsychotic
  • HALF-LIFE: 57 hours

FDA APPROVAL DATE: 04/29/2016

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Amiodarone, Carbamazepine, Chlorpromazine, Clarithromycin, Disopyramide, Drugs known to prolong the QT interval, Gatifloxacin, Indinavir, Itraconazole, Ketoconazole, Moxifloxacin, Phenytoin, Procainamide, Quinidine, Rifampin, Sotalol, St John's Wort, Strong CYP3A4 inhibitors and inducers, Thioridazine, Ziprasidone

PREGNANCY CATEGORY: N/A
No available data to inform drug-associated risk

BLACK BOX WARNING
INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

See full prescribing information for complete boxed warning

Our database has 21 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
OTHER.


Page last updated 08/01/2022

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top